Gilead: Teva Files ANDA With FDA for Generic Viread

Gilead Sciences, Inc. Thursday announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Viread (tenofovir disoproxil fumarate).
StreetInsider